Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost

Abstract

Aims To estimate the annual cost of treatment for Type 2 diabetic patients in Greece and investigate the effect of blood glucose regulation on patient cost.Methods A multipoint data collection procedure based on the patient records of 51 geographically distributed physicians was used in order to obtain the necessary data for the analysis and the construction of the patient cost model. Patients were classified as controlled (i.e. maintaining blood glucose regulation for the 1 year retrospective time frame of the analysis) and noncontrolled (the patients failing to do so in the specified time period). Cost categories included pharmaceutical expenditure, laboratory ⁄ diagnostic tests and consultation fees. Costs attributable to hospitalizations due to diabetic complications were not included. Calculations were based on 2007 fees and prices, and costs are expressed in Euros.Results The average annual cost of treatment for controlled patients was estimated at 981.72€ (95% confidence interval, 940.66-1023.01€), whereas for non-controlled patients it was 1566.12€ (95% confidence interval, 1485.42-1650.20€). Noncontrolled patients had 29.7% higher annual pharmaceutical costs (340.50 vs. 441.96€), 70% higher costs for laboratory ⁄ diagnostic tests (422.54 vs. 718.49€) and 85.5% higher consultation costs (218.68 vs. 405.67€) compared with their controlled peers. The average cost for a Type 2 diabetic patient in Greece, regardless of blood glucose regulation, was 1297.30€ (95% confidence interval, 1244.42-1349.61€).Conclusions Failing to control blood glucose levels within 'glycaemic goals', apart from the clinical consequences, can also have a significant financial impact, resulting in a 59.5% increase in the mean annual patient cost. Diabet. Med. 27, 679-684 (2010)

Antidiabetic potential of <i>Conocarpus lancifolius</i>

“…It is characterized by hyperglycemia in postprandial and fasting state, and its severe form is accompanied by ketosis and protein wasting (Athanasakis et al, 2010).…”

The Impact of Economic Crisis on Chronic Patients’ Self-Rated Health, Health Expenditures and Health Services Utilization

“…These diseases were chosen on grounds of epidemiology and disease burden [9], as well as their socioeconomic impact on the Greek healthcare system [10][11][12]. The sample size was determined according to the prevalence of each condition.…”

Cost-Minimization Analysis of Linagliptin Compared to Sitagliptin in the Treatment of Type 2 Diabetes Mellitus from a Turkish Healthcare Perspective

“…Table 2 shows the distribution of laboratory tests that are performed on DM patients during diagnostic workup and treatment follow-up. The tests are the routine laboratory tests that are recommended by the diagnosis and treatment guidelines as part of the routine practice, and the number of repeated tests within a year was obtained from the literature [50]. Distribution of treatment options for T2DM in the study population is as follows: single OAD in 54.7%; double and triple OAD in 29.4%; insulin in 3.0%; OAD and insulin in 12.9% of patients.…”